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Available online 14 March 2004Time for primary review 24 daysAbstractBased on recent advances, this article aims to review the biological basis for the use of either radiation or drug-eluting stents for
the prevention of restenosis, and to elucidate the complementary role that they may play in the future. Vascular restenosis is a
multifactorial process primarily driven by the remodeling of the arterial wall, as well as by the hyperproliferation of smooth muscle
cells (SMC). These pathophysiological features are the target of therapeutic strategies aimed at inhibiting constrictive remodeling as
well as inhibiting SMC proliferation. The success of radiation as well as anti-proliferative drugs such as paclitaxel and sirolimus lies in
the primary and/or multifactorial inhibition of cell proliferation. Radiation has the additional feature of preventing constrictive
remodeling while sirolimus has the potential property of being anti-inflammatory, which may be a desirable feature. The effects of
radiation are not reliant on any uptake and ‘‘metabolism’’ by the target cells, as in the case with drugs, and thus radiation potentially
may be more effective as a result of its more-direct action. However, radiation does have some significant drawbacks compared to
drug-eluting stents, including a much delayed re-endothelialization resulting in the need for prolonged anti-platelet therapy. Based on
recent clinical data, drug-eluting stents have been shown to markedly reduce the likelihood of restenosis, which actually favors this
approach for the prevention of restenosis. From a biological perspective, drug-eluting stents and radiation have certain differences,
which are reviewed in this article.
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1. Introduction in the mid 1970s [2–6]. This process has been considered toMore than 1.5 million percutaneous interventions are
performed worldwide each year for coronary disease [1].
The recurrence of obstructive lesions, or restenosis, has been
the major complication of percutaneous transluminal coro-
nary angioplasty (PTCA) since its introduction by Gruentzig0008-6363/$ - see front matter D 2004 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2004.02.001
* Corresponding author. Tel.: +43-1-260-021667; fax: +43-1-26007-
21667.
E-mail address: j.hendry@iaea.org (J.H. Hendry).occur as a result of three separate mechanisms: (1) elastic
vascular recoil, (2) neointimal hyperplasia and matrix de-
position and (3) constrictive remodeling.
The rationale for delivering ionizing radiation to the sites
of coronary angioplasty and stenting, to prevent restenosis,
emerged from the understanding that neointimal hyperplasia
represented a proliferative response to PTCA and stenting.
Radiation represented a potentially effective means of deal-
ing with that response [7–10]. Trials of intra-luminal irradi-
ation, either using a radioisotopic stent or intra-luminal
brachytherapy, have revealed impressive results, with up to
fourfold decreases in restenosis reported [11]. Several studiesed by Elsevier B.V. All rights reserved.
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emitters (SCRIPPS [12] and GAMMA 1 [13]) and beta-
emitters (Beta-wrist [14] and START [15]) for the treatment
of in-stent restenosis. All of these have shown positive
benefits from the use of radiation. The situation is different
for the treatment of newly diagnosed stenosis with radioac-
tive stents or intra-luminal brachytherapy. The studies have
either revealed aneurysmatic alterations of vessels [16], edge
effects (stenosis or restenosis at the proximal and/or distal end
of an irradiated segment) [17,18], or simply have failed to
show any prevention of restenosis [19,20]. It appears that
intra-luminal irradiation is a promising tool for the treatment
of in-stent restenosis, while the irradiation of newly diag-
nosed stenosis fails to show a positive benefit. However, there
are two important complications related to the use of brachy-
therapy—an edge restenosis (candy-wrapper effect) and the
risk of late thrombosis. Edge restenosis was first noted with
the use of radioactive stents, and it is considered to be the
result of the fall-off in the radiation dose at the edges (ends) of
the stent. It has been proposed that this may exert a prolifer-
ative stimulus—as described in vitro [21]—on the smooth
muscle cells (SMC) of the vessel wall resulting in a neointima
at the site of the stent edges after these lower doses of
irradiation.
Besides the advantage of successfully preventing the
recoil mechanism, the implantation of a stent offers the
opportunity to use it as a vehicle for local drug delivery.
Several compounds such as sirolimus, tacrolimus, ever-
olimus, paclitaxel, QuaDS-QP-2, actinomycin D, heparin
and dexamethasone have been tested for stent coating,
primarily with the aim of the inhibition of SMC prolifer-
ation. Among these compounds most experience has been
gathered for sirolimus and paclitaxel, and additional stud-
ies for related compounds are published or in preparation.
The ‘‘First in man’’ experience of sirolimus-coated stents
was reported by Sousa et al. [22,23] from Brazil and most
recently this group reported the lack of restenosis in a 2-
year follow up after implantation of sirolimus-coated stents
in human coronary arteries with newly diagnosed stenosis.
Subsequent multicenter randomized trials (e.g. the RAVEL
trial) essentially confirmed the results of the initial feasi-
bility study with again overwhelming success in the
prevention of restenosis after implantation of a sirolimus-
coated stent [24,25]. These studies have been criticized for
the favourable patient population enrolled. Subsequent
multicenter trials, the SIRIUS trial and E-SIRIUS trial,
were recently reported showing a clear benefit for the
treatment of complex coronary lesions/single-long-athero-
sclerotic coronary lesions by sirolimus-eluting stents. Some
subgroups had less favourable outcomes but even in these
patients a profound benefit in comparison to controls was
observed [26,27]. Comparably promising results have been
obtained from the use of paclitaxel-coated stents, an anti-
proliferative compound which has also been shown to be
efficacious for the treatment of in-stent restenosis (AS-
PECT, Taxus I–III) [28–31].Apart from the clinical benefits of most types of drug-
eluting stents in the prevention of restenosis at least for newly
diagnosed lesions, the economic value of stenting versus
brachytherapy appears to be rather unpredictable at the
present stage. While the costs of drug-eluting stents are
determined by the stent on the one hand versus the decrease
in re-interventions [32,33], the use of brachytherapy will at
least require additional devices and the availability of a
radiation therapist. These costs have to be viewed in face of
the decrease in the number of re-interventions. The judge-
ment of the economic aspects is currently left to additional
studies. Nevertheless, given the recently reported efficacy of
most drug-eluting stents for the prevention of restenosis, it
seems timely to review the biological basis of intraluminal
irradiation and drug-coated stents and try to elucidate the
complementary role that they may play in the future.2. Radiation—intravascular brachytherapy
Numerous studies have consistently demonstrated re-
markable suppression of neointima formation using radiation
from a variety of isotopes delivered by an endoluminal
approach. At least three groups have documented similar
results in the pig coronary artery model of restenosis after
overstretch balloon injury, using the g-emitter 192Ir at roughly
comparable doses. Wiedermann et al. [34] found suppression
of neointimal formation 4 weeks after angioplasty when 20
Gy was given at a radial depth of 1.5 mm just before arterial
injury. Similarly, the group at Emory demonstrated a marked
suppression of neointima formation using 192Ir with a dose–
response effect in vessels irradiated with 3.5, 7, and 14Gy at a
radial depth of 2 mm. A continued benefit was seen at 6
months in arteries irradiated with 14 Gy [35,36]. One impor-
tant difference between the results reported from the Colum-
bia group and the Emory group is the effect of radiation dose
on outcome, i.e. the dose–response relationship. The Co-
lumbia group described beneficial effects of 15 and 20 Gy,
given at 1.5 mm from the center of the source, but the results
with 10 Gy showed greater neotintimal proliferation than in
controls. In contrast, the Emory group saw a beneficial effect
even with the lowest dose of 3.5 Gy (at 2mm). Further studies
by other authors have shown greater neointimal proliferation
at low doses (e.g. 5 Gy) compared to controls, suggesting that
balloon or stent injury combined with such low doses is a
poor combination. The partly contradictory results of the
radiation studies mentioned above may be based on two
general problems with such studies, the comparability of
animal models and the influence of radiation dose, dose
fractionation and penetration depth of the radiation. Howev-
er, although additional studies are required to resolve these
questions, the message taken from studies available so far is
that radiation at a certain minimal dose is capable of prevent-
ing neointimal proliferation.
Because of concerns about prolonged treatment times and
radiation safety problems associated with penetrating gam-
Fig. 1. Histological appearance of the inferior spinal artery of the spinal
cord of pigs after the local irradiation of the cervical spinal cord with a
single dose of 27.5 Gy of Co-60 gamma-rays: panel A: 10 weeks, shows
white blood cells accumulating in the lumen of the vessel and in the
subendothelial space. The subendothelial space also shows an accumulation
of hyline material (MSB stain), panel B: higher powered view of an
adjacent section to show the subendothelial changes (Luxol fast blue, PAS),
panel C: 14 weeks, shows almost complete occlusion of the vessel lumen
with loose connective tissue (Luxol fast blue, PAS) and panel D: 16 weeks,
almost complete occlusion of the lumen of the blood vessel with dense
connective tissue, myointimal proliferation (Luxol fast blue, PAS).
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studied the potential use of h-emitting isotopes (90Y, 90Sr/Y,
188Re and 186Re) in the prevention of restenosis. Verin et al.
[37] reported the use of a flexible 90Y coil deployed at the end
of a guidewire using a balloon catheter centering device, after
balloon injury in the carotid and iliac arteries of hypercho-
lesterolemic rabbits. They demonstrated a reduction in BrdU-
positive cells in the intima and media of arteries receiving 6,
12 or 18 Gy compared to controls; however at 6 weeks only
the 18 Gy dose was effective in reducing neointima forma-
tion. The Emory group examined the use of stainless-steel
encapsulated seeds containing 90Sr/Y [38]. The results of this
study indicated that after doses of 7 and 14 Gy (again at 2 mm
depth), healing at 2-weeks post-angioplasty in the coronary
artery was similar to that observed using 192Ir. Again, the
comparability of the results of radiation studies is hampered
by the use of different models (species, hypercholestrolemia)
and/or different radionuclides that actually reflects the com-
plex problem of restenosis and the multiple mechanisms to be
targeted. Further studies are required to evaluate the effec-
tiveness of radiation approaches especially regarding the
radiation penetration depth—because this determines the
vessel wall layers to be treated—and the risk factors for
arteriosclerosis and restenosis.
However, scanning electron microscopy and Indium-
labelled platelet studies have shown incomplete healing of
vessels with doses of z 15 Gy at 1 and 3 months follow-up
[39]. Inadequate endothelial recovery of an irradiated artery
after angioplasty renders its luminal surface prothrombotic,
and in the setting of an appropriate physiologic stimulus,
results in thrombotic occlusion. The problem of late throm-
bosis observed in clinical trials certainly is compatible with
the delayed healing observed in the animal studies.
Myointimal proliferation leading to variable degrees of
vessel occlusion can also represent a late consequence of
therapeutic radiation exposure even in the absence of balloon
injury. The effect may occur many years after exposure [40].
A chance observation in a study designed to investigate the
time sequence of changes in the spinal cord of pigs after
irradiation has, however, provided some insight into possible
mechanisms. Irradiation was carried out with a single dose of
27.5 Gy of 60Co gamma-rays to a 10 cm length of the cervical
spinal cord in 4-month-old female large white pigs [41]. The
observedmajor vessel changes were in themain ventral artery
within the lining of the spinal cord. At the earliest time point,
6 weeks after irradiation, there was qualitative evidence for a
reduction in the number of endothelial cells lining the wall of
this blood vessel. This observation is consistent with findings
for the microcirculation in simple model systems [42], where
a decline in endothelial cell number has been reported in the
first 4–8 months after irradiation. From 10 to 12 weeks after
exposure there had been the development of a clearly defined
sub-endothelial space, this contained hyaline material (Fig.
1A) and the infiltration of mononuclear cells from the blood.
White blood cell adherence to the endothelium and an excess
number of mononuclear cells in the lumen of the vessel werealso noted indicating chemo-attraction into the irradiated area
(Fig. 1B). By 12–14 weeks after irradiation the lumen of the
vessel was reduced to a varying degree and the sub-endothe-
lial space was filled by what appeared to be loose connective
tissue (Fig. 1C). At slightly later times (16–18 weeks) the
sub-endothelial space was filled with dense tissue resulting in
a varying degree of vessel occlusion (Fig. 1D). The internal
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adjacent to the locally irradiated vessel recently has been
reported [43]. This vasculitis was apparently unrelated to
dose. An inflammatory reaction was a consistent finding and
the possible role of the up-regulation of cytokines was
discussed. Comparable changes have also been reported in
microcirculation networks; for example, in the renal glomer-
uli of the pig after irradiation [44].
Cellular radiation responses involve both DNA-damage-
dependent and DNA-damage-independent signalling path-
ways. As outlined in Fig. 2, DNA-damage, mainly DNA-
double strand breaks, is able to activate the protein kinases
ATM and DNA-PK, both located in the cell nucleus. ATM
and DNA-PK will then phosphorylate p53 in specific serine
residues, which results in the stabilisation and activation of
the tumor suppressor protein p53 [45]. Once p53 is activat-
ed, it acts as a transcription factor and induces the expres-
sion of the p21-protein, a product of the WAF/CIP1 gene
[46,47]. This protein accumulates in the cell nucleus and
inactivates the activity of cyclin dependent kinase (cdk2)/
cyclin E complexes. This leads to a block in cell cycle
progression and arrests cells in G1-phase to allow time for
the repair of DNA-damage. Cells with accurately repaired
DNA can re-enter the cell cycle and progress through S-
phase into mitosis. Thus, DNA-damage repair is necessary
for cell survival and undisturbed proliferation followingFig. 2. Radiation-induced DNA-damage results in the induction of a variety
of molecular signals leading to damage recognition, cell cycle arrest and
DNA repair. The interaction of this network of molecular events determines
the cellular fate, i.e. cell death or cell survival. DNA double-strand breaks
mainly are responsible for the activation of specific proteins, which are
involved in damage sensing like the ATM protein, or in DNA repair like
DNA-Protein Kinase (DNA-PK). Both proteins, however, activate/stabilize
the tumor suppressor protein p53, which is a major control protein in
regulating cell cycle arrest and transactivation of DNA repair-relevant genes
as well as genes controlling apoptotic pathways. As a result of successful
DNA-repair irradiated cells will survive the radiation insult and re-enter cell
cycle for undisturbed proliferation. In the case of non-successful DNA-
repair, cells can either enter directly the apoptotic pathway mainly under the
control of p53 or go through a limited number of cell cycles, which will
result in the so-called mitotic or reproductive cell death due to severe
problems in distributing the incorrect-repaired DNA/chromosomes during
mitosis.radiation exposure. When DNA double-strand breaks are
incorrectly repaired during G1-arrest then the cell might
encounter severe problems in distributing DNA/chromo-
somes in the following mitosis that may result in mitotic/
reproductive cell death. The latent period for expression of
this injury can be very variable, ranging from short times
post-irradiation in rapidly dividing cells to very long times
in near-quiescent cell populations in vivo.
Recently, it has been shown that the upregulation of the
tumor suppressor gene PTEN inhibits the proliferation,
migration and survival of vascular SMC by blocking the
AKT and FAK-dependent signalling cascades [48]. Expres-
sion of PTEN has been shown to be upregulated by
radiation through a mechanism involving the activation of
the early growth response-1 gene, Egr-1 [49]. Egr-1 activity
can be increased several fold by radiation doses greater than
4 Gy in a variety of cell types [50,51]. Therefore, it seems
very likely that DNA-damage-independent induction of
PTEN may contribute to the inhibitory effect of radiation
on vascular SMC proliferation and migration.
A substantial literature has accumulated on the effects
of ionizing radiation on the cellular components of blood
vessels. For endothelium, a variety of molecular phenom-
ena have been examined ranging from the function of
lipoprotein receptors to adhesion molecule expression. For
the most part it can be stated that endothelium is much
more sensitive to the late effects of irradiation than are the
other cellular residents of the arterial wall. The importance
of the radiosensitivity of arterial endothelium in a setting
of acute angioplasty is probably negligible insofar as the
actual site is concerned, since perhaps >90% of the
endothelium is denuded by the procedure. However, en-
dothelium from branch arteries or in the vasa vasorum
could play a significant role in postangioplasty healing and
might easily be influenced by endovascular irradiation
particularly from a penetrating gamma-emitter or external
irradiation.3. Drug-eluting stents
3.1. Drug-dose responses in vitro
The influence of various kinds of compounds for the
inhibition of SMC proliferation to prevent restenosis has
been tested. HMG-CoA reductase inhibitors have been
studied extensively both in vitro [52,53] as well as clinically
[54–57]. Other compounds studied include corticosteroids
[58], calcium antagonists [59] or angiotensin converting
enzyme inhibitors [60,61]. A general problem using the
systemic application of single compounds for antiprolifer-
ative purposes is that concentrations needed in vitro for the
required effects cannot be easily achieved in vivo due to
critical side effects. This has led to the current situation in
that no compound tested so far has made a major contribu-
tion to the prevention of restenosis [62].
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and antiproliferative properties on a variety of cell lines over
several years. This compound mimics a starvation-like
signal as distinct from amino acid and glucose deprivation
[63]. It acts during both co-stimulatory activation and
cytokine-driven pathways via a unique mechanism: inhibi-
tion of a multifunctional serine–threonine kinase, the mam-
malian target of rapamycin (= sirolimus) (mTOR) [64].
Sirolimus forms a complex with FKBP12, which inhibits
mTOR activation resulting in sustained p27 kip1 levels and
inhibition of pRb phosphorylation as well as impaired DNA
synthesis by inhibition of p70S6K kinase [65–69]. Regard-
ing vascular biology, special interest is linked to the prolif-
eration of SMC and fibroblasts. Primary fibroblast cultures
have been exposed to sirolimus at concentrations of 0.1–
100 ng/ml with or without platelet derived growth factor
(PDGF) or basic fibroblast growth factor (bFGF). Interest-
ingly, none of the concentrations of sirolimus used induced
cytotoxic reactions, but an inhibition of PDGF—as well as
bFGF-induced proliferation was observed after all doses of
the compound used. For PDGF the most marked effect
(60% inhibition of proliferation) was observed with 30 ng/
ml while for bFGF the effects were less pronounced (37%
inhibition) and was optimal at 10 ng/ml [70]. A similar
inhibition of growth factor effects was found for sirolimus
(10 ng/ml) using rat hepatocytes [71]. For vascular SMC,
concentrations as low as 1 ng/ml have been shown to exert
antiproliferative effects in vitro [65]. The inhibition of
growth factor effects was much greater than that of other
immunosuppressants such as cyclosporin A or FK506 [72],
which exemplifies the special role of sirolimus for inhibition
of cell proliferation. This is presumably caused by its
mechanism of inhibiting mTOR. Sun et.al. [73] have shown
that the effect of sirolimus in vitro is not only restricted to
SMC proliferation but sirolimus also inhibits the bFGF-
driven migration of SMC. This effect is dependent on p27.
This again indicates the involvement of the mTOR pathway.
The inhibition of cell migration has been studied on both
human and rat SMC, and it was found to be significantly
reduced by sirolimus at doses of 2 ng/ml [66].
The other compound of pivotal interest for stent coating
is paclitaxel, which has been shown to exert antiproliferative
effects on SMC at concentrations several orders of magni-
tude lower than those used for the treatment of cancer. The
compound acts by inducing cellular microtubules to form
stable chains with resulting G0/G1 and G2/M arrest [74].
Concentrations higher than 10 nmol/l show antiproliferative
effects on bovine coronary SMC [75], while studies on
human arterial SMC showed a 50% reduction in cell
proliferation at concentrations as low as 2 nmol/l in both
monocultures and cocultures with human arterial endothelial
cells [76]. Remarkably, the antiproliferative effect can be
considerably enhanced in a supra-additive fashion by the
combined use of paclitaxel with cyclosporine A, via the
activation of the protein kinase C pathway [75]. Also,
paclitaxel is a chemotherapeutic compound clearly capableof inducing apoptosis. Studies on DNA fragmentation
revealed that the dose–responses for the induction of
apoptosis are at least partially related to the antiproliferative
effects [75], which is not the case for the dose responses
using sirolimus.
3.2. Drug-dose response and latencies in vivo
Besides the advantage of successfully preventing the
recoil mechanism, the implantation of a stent offers the
opportunity to use it as a vehicle for drug delivery. To allow
a controlled drug release, a variety of biomaterials/polymers
such as copoly(ester-amide)elastomers [77] and phosphor-
ylcholine have been tested especially with view to drug
release fromulas, a reduction in platelet and protein adhe-
sion, and the capability of an endothelialization of the stent
[78–81]. Progress with such polymers has founded the era
of drug-coated stents.
The use of sirolimus-coated stents or stents coated with
related drugs shows promise for eliminating the problem of
in-stent restenosis. Results obtained from animal models as
well as clinical studies have been so overwhelming that
leading cardiologists in the field talk about a ‘‘turning point
in cardiology’’ [82]. In the meantime several studies have
shown the consistent finding of largely impaired neointima
formation in both animal models [83,84] and in patients for
a variety of arteries, such as femoral and coronary arteries
[22,23,85,86]. A drug load of 185 Ag sirolimus per stent
successfully reduced neointima formation in a porcine
injury model [84]. From the data available so far, siroli-
mus-coated stents may abrogate the problem of in-stent
restenosis and may challenge the clinical outcome of coro-
nary-artery bypass grafting under certain conditions. There
are developments such as a sirolimus-coated stent that
utilizes a non-erodable methacrylate copolymer matrix with
a 30% drug-to-polymer ratio, by weight. A thin coating of
5–10 Am is applied to a Bx Velocity stent (Cordis, Johnson
& Johnson) with a total quantity of 185 Ag (140 Ag/cm2).
This is delivered in a slow release formula over a period of 4
weeks. Despite local delivery of the drug, peak systemic
concentrations occur 1 h after implantation of the sirolimus-
coated stent. This amount is about 10% of those levels
applied for systemic immunosuppressive purposes. The
decline below the detectable level of 0.4 ng/ml occurred
within 3 days [87,88].
For paclitaxel, several polymer coatings such as pLA/
pLC, polymer sleeves and CSG, with drug loadings between
0.2 and 200 Ag in slow and fast release formulations, have
been used [88]. Paclitaxel loadings of 0.2–187 Ag per stent
have been tested in a porcine model of restenosis with a
resulting 84% reduction in neointima formation at a drug
load of 187 Ag per stent [89]. Although an effective
inhibition of neointimal formation has been shown by these
approaches, there is also a dose-dependent cytotoxic effect,
which results in impaired wound healing, persistent intimal
fibrin deposition, intra-intimal haemorrhage as well as
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strated in animal studies [90].Table 1
Comparison of biological features of radiation and drug-coated stents
Feature Radiation Coated stent
Recoil no acute effect total prevention
Vasomotor acute loss of
vasodilatory effects
blocked
Remodeling prevents constrictive
remodeling
constrictive remodeling
or incomplete apposition
Cell G0/G1 and G2 arrest depending on drug:
proliferation p53! p21
(WAF1/CIP1) delay of
cell cycle progression
paclitaxel: primarily G2/M
(micro-tubules) but also
G1 arrest
Treatment of various
vascular layers
depending on radiation
penetration depth
sirolimus: G1/S delay
(p27, pRb, p70S6K kinase)
Apoptosis not in therapeutic doses paclitaxel: depending on dose
sirolimus: probably not
Inflammation present paclitaxel: present
sirolimus: potential inhibition4. Summary and conclusions
Drug-eluting stents have been shown to markedly reduce
the likelihood of restenosis when applied to relatively short
lesions in previously untreated coronary vessels, and recent
studies have also revealed the success of drug-eluting stents
for the treatment of more complex coronary lesions and the
treatment of in-stent restenosis [22–31]. Presuming that
there is a sustained benefit from these devices, it is likely
that widespread adoption of this technology will reduce the
frequency of in-stent restenosis, the main target of intra-
vascular brachytherapy at this time. If the application of
drug-eluting stents continues to prove to be an effective and
safe treatment for in-stent restenosis, then it is likely that this
therapy will be adopted in lieu of intra-vascular brachyther-
apy in the light of simpler logistics, and vascular brachy-
therapy will be reserved for very limited number of niche
applications. However, irradiation is still useful for periph-
eral vascular sites where drug-coated stents may have less
utility.
Nevertheless, vascular brachytherapy has some advan-
tages compared to drug eluting stents. Because the radiation
source train may be repositioned within the vessel to treat
longer lesions or lesions in multiple vessels it may have cost
advantages compared with drug-eluting stents. In addition,
it is likely that a radiation catheter may be able to be used at
sites where it is impossible to deliver a stent, i.e. within a
previously deployed stent or in some tortuous, highly
angulated, small vessels or at very distal arterial locations.
There may also be situations where a stent is undesirable
because it may ‘‘jail’’ a side-branch or will not allow normal
artery bending. The advantage of radiation in those lesions,
situated at sites of arterial bifurcations or at highly flexible
arterial locations such as the popliteal artery, is that the anti-
proliferative treatment could be delivered without placing a
stent. From a mechanistic point of view, the effect of
radiation is independent of its uptake and ‘‘metabolism’’
by the target cells and may be potentially more effective as a
result of its more-direct action. All of the above mentioned
considerations imply that radiation treatment is more flex-
ible compared to drug-eluting stents, allowing the anti-
restenotic therapy to be delivered independently from the
stenting, for any desired segment length and anatomic
location. In addition, the radiation dose and dose distribu-
tion can be varied and adjusted as desired and may even be
repeated.
Radiation does have some significant drawbacks com-
pared to drug-eluting stents, including a much delayed re-
endothelialization resulting in the need for prolonged anti-
platelet therapy (Clopidogrel and Aspirin) particularly in the
stented patient. On the other hand, late stent-thrombosis
may also be an issue for drug-eluting stents under certainconditions. However, the potential for late radiation injury
would appear to be more likely than with the drug-eluting
stent.
The biology of radiation effects is different from the
effects produced by sirolimus or paclitaxel. Although radi-
ation has the advantage of inducing positive or adaptive
remodeling [91], this feature may be less important regard-
ing in-stent restenosis, since in this situation an outward
remodeling of the vessel wall is limited by the stent itself or
may even result in incomplete apposition. The typical effect
of radiation is DNA damage in various cell types including
endothelial cells, smooth muscle cells and fibroblasts,
depending on the radiation penetration depth into the vessel
wall.
From the biological standpoint, the question as to which
is the best approach can be answered only with regard to
several biological and clinical issues such as recoil, vessel
remodeling, cell proliferation, apoptosis and local inflam-
mation (see Table 1). Stenting itself has the clear advan-
tage of resulting in an effective prevention of recoil. It is
also eminently successful in the case of plaque instability
and intraluminal thrombus. The success of radiation as
well as antiproliferative drugs such as paclitaxel and
sirolimus or related compounds lies in the inhibition of
cell proliferation. Nonetheless, the success of sirolimus
raises the question about its potential biological advantage
over other approaches. From the data available so far it
may be that the combination of antiproliferative plus
potential anti-inflammatory effects allows the stent to be
‘‘more quietly’’ integrated into the vessel wall than when
radiation is used. Further studies will be needed to elab-
orate on this hypothesis.
The mechanisms of action of brachytherapy and drug
coated stents are not completely understood. In general,
both radiation and the most effective drug coatings (Siroli-
mus, Paclitaxel) are anti-proliferative. Sirolimus has the
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which may be an additional desirable feature. On the other
hand the effect of radiation on inflammation in the vessel
wall has not been evaluated. The largest deficiency that
exists in the preclinical evaluation of both drug-eluting
stents and vascular brachytherapy is the fact that most of
these studies have been carried out in non-atherosclerotic
vessels.
It seems likely that radiation will continue to find ap-
plication in certain subsets of patients with in-stent reste-
nosis. Economic considerations may promote its continued
use for other indications. Given the above, continued inves-
tigation of critical clinical issues in preclinical models and
long-term follow-up of irradiated patients and in patients
receiving drug-eluting stents seems warranted.
Hence there remain several unanswered questions re-
garding the use of radiation or drugs as the preferred agent
in the ‘‘antiproliferative’’ treatment of restenosis. Points
requiring clarification include:
(1) The role of inflammatory responses and anti-inflamma-
tory drugs in the treated and adjacent vessels.
(2) The effect of radiation or drugs on the progression of
atherosclerotic changes in vessels.
(3) Studies of any late effects after drug treatments in
comparison to those known after irradiation treatments.
(4) The influence of prior irradiation on the subsequent
response to drug treatment.Acknowledgements
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